DE60136811D1 - Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren - Google Patents

Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren

Info

Publication number
DE60136811D1
DE60136811D1 DE60136811T DE60136811T DE60136811D1 DE 60136811 D1 DE60136811 D1 DE 60136811D1 DE 60136811 T DE60136811 T DE 60136811T DE 60136811 T DE60136811 T DE 60136811T DE 60136811 D1 DE60136811 D1 DE 60136811D1
Authority
DE
Germany
Prior art keywords
gene
rsv
genes
genome
shifted
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60136811T
Other languages
German (de)
English (en)
Inventor
Christine D Krempl
Peter L Collins
Brian R Murphy
Ursula Buchholz
Stephen S Whitehead
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Application granted granted Critical
Publication of DE60136811D1 publication Critical patent/DE60136811D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18522—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18541—Use of virus, viral particle or viral elements as a vector
    • C12N2760/18543—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18561—Methods of inactivation or attenuation
    • C12N2760/18562—Methods of inactivation or attenuation by genetic engineering

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DE60136811T 2000-06-23 2001-06-22 Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren Expired - Lifetime DE60136811D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21370800P 2000-06-23 2000-06-23
PCT/US2001/020107 WO2002000693A2 (en) 2000-06-23 2001-06-22 Respiratory syncytial virus vaccines expressing protective antigens from promotor-proximal genes

Publications (1)

Publication Number Publication Date
DE60136811D1 true DE60136811D1 (de) 2009-01-15

Family

ID=22796187

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60136811T Expired - Lifetime DE60136811D1 (de) 2000-06-23 2001-06-22 Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren

Country Status (13)

Country Link
EP (1) EP1294858B1 (enExample)
JP (1) JP2004515218A (enExample)
KR (1) KR100899030B1 (enExample)
CN (1) CN1468301A (enExample)
AT (1) ATE416251T1 (enExample)
AU (3) AU6870901A (enExample)
BR (1) BRPI0112276B8 (enExample)
CA (1) CA2413786A1 (enExample)
DE (1) DE60136811D1 (enExample)
ES (1) ES2317914T3 (enExample)
IL (1) IL153530A0 (enExample)
MX (1) MXPA02012818A (enExample)
WO (1) WO2002000693A2 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003530073A (ja) * 1999-07-09 2003-10-14 アメリカ合衆国 弱毒化されたヒト−ウシキメラ呼吸器合胞体ウィルスワクチンの製造
WO2008094200A2 (en) * 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc Chimeric virus-like particles
WO2008094197A2 (en) 2006-07-27 2008-08-07 Ligocyte Pharmaceuticals, Inc. Chimeric influenza virus-like particles
WO2011056899A2 (en) 2009-11-03 2011-05-12 Ligocyte Pharmaceuticals, Inc. Chimeric rsv-f polypeptide and lentivirus or alpha-retrovirus gag-based vlps
CN105200069A (zh) * 2015-10-16 2015-12-30 北京交通大学 基于rna聚合酶ⅰ的rsv微型复制基因组及其应用
CA3007474A1 (en) * 2015-12-11 2017-06-15 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Recombinant respiratory syncytial virus strains comprising ns1 and ns2 gene shifts
CN110229219B (zh) * 2019-06-21 2021-03-30 中国科学院武汉病毒研究所 一种新型的呼吸道合胞病毒疫苗抗原的制备方法及其用途

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2112220A3 (en) * 1996-07-15 2010-01-06 The Government of the United States of America, as represented by The Department of Health and Human Services Production of attenuated respiratory syncytial virus vaccines from cloned nucleotide sequences

Also Published As

Publication number Publication date
BRPI0112276B1 (pt) 2019-12-31
ATE416251T1 (de) 2008-12-15
ES2317914T3 (es) 2009-05-01
CA2413786A1 (en) 2002-01-03
CN1468301A (zh) 2004-01-14
IL153530A0 (en) 2003-07-06
EP1294858B1 (en) 2008-12-03
KR100899030B1 (ko) 2009-05-21
AU6870901A (en) 2002-01-08
KR20030045685A (ko) 2003-06-11
WO2002000693A3 (en) 2002-09-26
BRPI0112276B8 (pt) 2021-05-25
MXPA02012818A (es) 2003-05-14
WO2002000693A2 (en) 2002-01-03
AU2006252238A1 (en) 2007-01-25
EP1294858A2 (en) 2003-03-26
JP2004515218A (ja) 2004-05-27
AU2001268709B2 (en) 2006-09-28
BR0112276A (pt) 2004-02-10

Similar Documents

Publication Publication Date Title
ATE419369T1 (de) Chimäre mensch-rinder respiratory syncytial virus vakzinen
Lu et al. A safe and highly efficacious measles virus-based vaccine expressing SARS-CoV-2 stabilized prefusion spike
WO2001042445A3 (en) USE OF RECOMBINANT PARAINFLUENZA VIRUSES (PIVs) AS VECTORS TO PROTECT AGAINST INFECTION AND DISEASE CAUSED BY PIV AND OTHER HUMAN PATHOGENS
Toro et al. Infectious bronchitis virus S2 expressed from recombinant virus confers broad protection against challenge
MXPA01013302A (es) Vacunas para el virus de la parainfluenza (piv) quimerico para humanos-bovinos atenuadas.
CA2230033A1 (en) Production of infectious respiratory syncytial virus from cloned nucleotide sequences
DE69739689D1 (de) Herstellung von attenuierten respiratorischen syncytialvirus-impfstoffen aus klonierten nukleotidsequenzen
ATE85622T1 (de) Chimarenglykoproteine, enthaltend immunogene segmente des humanen respiratorischen synzytialvirus.
Cibulski et al. A novel Anelloviridae species detected in Tadarida brasiliensis bats: first sequence of a chiropteran Anellovirus
Schreur et al. Four-segmented Rift Valley fever virus induces sterile immunity in sheep after a single vaccination
WO2010079505A3 (en) Combined measles-human papilloma vaccine
DE60136811D1 (de) Respiratorische synzytialvirus impfstoffe, welche schützende antigene von promotor-proximalen genen exprimieren
PH12020500526A1 (en) Paramyxoviridae expression system
BR0011160A (pt) Produção de vacinas de vìrus sinciciais respiratórios quiméricos atenuados a partiir de sequências de nucleotìdeos clonados
JP2020534284A5 (enExample)
WO2008048984A3 (en) Methods and compositions for preparing a universal influenza vaccine
BRPI0504945B8 (pt) Método para a produção de flavivirus recombinante contendo sequências de nucleotídeos codificantes de uma proteína heteróloga, constructo de dna, flavivirus, e, composição vacinal para imunizar contra flavivirus e/ou outros patógenos.
Nagata et al. Efficacy of DNA vaccination against western equine encephalitis virus infection
Herfst et al. Vaccination approaches to combat human metapneumovirus lower respiratory tract infections
Bartlett et al. Human parainfluenza virus type I (HPIV1) vaccine candidates designed by reverse genetics are attenuated and efficacious in African green monkeys
ZA202101156B (en) New attenuated virus strain and use thereof as a vaccine
Nam et al. genetic heterogeneity of Japanese encephalitis virus assessed via analysis of the full-length genome sequence of a Korean isolate.
Zanetti et al. Evaluation of modified vaccinia virus Ankara expressing VP2 protein of infectious bursal disease virus as an immunogen in chickens
Marmonier et al. The coat protein determines the specificity of virus transmission by Xiphinema diversicaudatum
WO2002002605A3 (en) Attenuated human-bovine chimeric parainfluenza virus (piv) vaccines

Legal Events

Date Code Title Description
8364 No opposition during term of opposition